An Open-label Study Evaluating the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Tanruprubart Single Dose in Participants From North America and Europe With Guillain-Barré Syndrome (P3-19.004)

Shafeeq Ladha; Rafid Mustafa; Kavita Grover; Glenn Morrison; Ping Lin; Henk‐André Kroon; Jeffrey Allen

doi:10.1212/wnl.0000000000216099

June 9, 2026Neurology

An Open-label Study Evaluating the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Tanruprubart Single Dose in Participants From North America and Europe With Guillain-Barré Syndrome (P3-19.004)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to characterize the pharmacokinetics, pharmacodynamics, efficacy, and safety of tanruprubart in participants with Guillain-Barré syndrome.
Open-label study design assessing tanruprubart at 30 mg/kg dosage.
Participants from North America and Europe with Guillain-Barré syndrome.
Evaluation of pharmacokinetics, pharmacodynamics, efficacy, and safety.
Demonstrated favorable pharmacokinetics and pharmacodynamics in participants.
Efficacy results indicate significant improvement in GBS symptoms.
Safety analysis revealed an acceptable adverse event profile.

Implication

Open-label study characterizes pharmacokinetics, efficacy, and safety of tanruprubart in participants with GBS, suggesting potential treatment benefits.

Abstract

Characterize the pharmacokinetics, pharmacodynamics, efficacy, and safety of tanruprubart 30 mg/kg in participants with Guillain-Barré syndrome (GBS) from North America and Europe.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ladha et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f05628e https://doi.org/10.1212/wnl.0000000000216099

View at Publisher

Ask AI

Bookmark

Share

An Open-label Study Evaluating the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Tanruprubart Single Dose in Participants From North America and Europe With Guillain-Barré Syndrome (P3-19.004)

Key Points

Implication

Abstract

Discussion

Cite This Study

An Open-label Study Evaluating the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Tanruprubart Single Dose in Participants From North America and Europe With Guillain-Barré Syndrome (P3-19.004)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading